1. BY: PALAK BHARDWAJ GAURAV SATIA VARUN KALIA

3. Sales in Over 125 Countries

4. 2008 Revenue: $ 1.7 Billion

5. 80 % International; 20% India

6. Ground Presence in 49 Countries

7. Global Team with Global Mindset

9. BUSINESS MODEL

10. ERA OF GENERICS……………. Generic is a bioequilvent copy of formulation drug,legally manufacture and marketed after patent Expiry of an innovator drug.

11. 6 Growth of Global Market of generics 1998 – 2008 Turn over in USD Billion

13. Slow temp of innovations and decrease of number of new molecules,

14. deficit of social and medical insurance funds, health sector reforms aimed to cut-down drug and therapy spending,WHO recommends usage of Generics to make essential drugs more accessible to the people, especially the developing countries.

15. Growth of genericsin Billion USD

16. PROJECTED TO GROW AT 11-13% OVER NEXT 3-5 YEARS

17. RANBAXY REACH IN CHINA…… Rannbaxy Laboratories has sold its Chinese JV, Ranbaxy Guangzhou China Limited (RGCL) Gareth Macdonald, 05-Jan-2010 This transaction is part of Ranbaxy’s endeavour to develop a new business model for China which entails the marketing of value added pharmaceutical formulations and the consolidation of manufacturing operations, for cost synergies.”

18. CONT………………USA $258 Billion market(in 2005). 50% of global sales $558 billion. FACTS:- - Lipitor earned $36 million revenues. - Ranbaxy launched donepezil 5mg/10mg

19. THANK YOU